Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.46 Million EUR | 62.88% |
| 2022 | -12.02 Million EUR | -395.22% |
| 2021 | -2.42 Million EUR | 79.22% |
| 2020 | -11.68 Million EUR | 31.34% |
| 2019 | -17.02 Million EUR | -34.1% |
| 2018 | -12.69 Million EUR | -24.01% |
| 2017 | -10.23 Million EUR | 8.3% |
| 2016 | -11.16 Million EUR | -24.22% |
| 2015 | -8.98 Million EUR | -1.48% |
| 2014 | -8.85 Million EUR | -19.47% |
| 2013 | -7.41 Million EUR | 39.24% |
| 2012 | -12.19 Million EUR | 21.69% |
| 2011 | -15.57 Million EUR | -35.72% |
| 2010 | -11.47 Million EUR | -12.26% |
| 2009 | -10.22 Million EUR | 16.69% |
| 2008 | -12.27 Million EUR | 6.69% |
| 2007 | -13.15 Million EUR | 14.61% |
| 2006 | -15.4 Million EUR | -275.26% |
| 2005 | 8.78 Million EUR | -19.93% |
| 2004 | 10.97 Million EUR | 63.56% |
| 2003 | 6.71 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -4.46 Million EUR | 62.88% |
| 2023 Q4 | 1.88 Million EUR | 0.0% |
| 2023 Q2 | -2.63 Million EUR | 52.91% |
| 2023 Q1 | -5.59 Million EUR | 14.06% |
| 2023 Q3 | 1.88 Million EUR | 171.41% |
| 2022 Q3 | -1.56 Million EUR | -19.91% |
| 2022 Q1 | -2.65 Million EUR | -52.96% |
| 2022 Q4 | -6.5 Million EUR | -317.05% |
| 2022 FY | -12.02 Million EUR | -395.22% |
| 2022 Q2 | -1.3 Million EUR | 51.04% |
| 2021 Q3 | 2.83 Million EUR | 221.87% |
| 2021 Q4 | -1.73 Million EUR | -161.25% |
| 2021 FY | -2.42 Million EUR | 79.22% |
| 2021 Q1 | -1.2 Million EUR | 53.4% |
| 2021 Q2 | -2.32 Million EUR | -93.76% |
| 2020 FY | -11.68 Million EUR | 31.34% |
| 2020 Q3 | -2.75 Million EUR | 18.35% |
| 2020 Q1 | -2.98 Million EUR | 57.46% |
| 2020 Q2 | -3.37 Million EUR | -13.11% |
| 2020 Q4 | -2.57 Million EUR | 6.43% |
| 2019 FY | -17.02 Million EUR | -34.1% |
| 2019 Q1 | -3.01 Million EUR | 23.5% |
| 2019 Q2 | -4.39 Million EUR | -45.73% |
| 2019 Q3 | -2.59 Million EUR | 41.02% |
| 2019 Q4 | -7.01 Million EUR | -170.24% |
| 2018 Q3 | -2.97 Million EUR | -16.44% |
| 2018 FY | -12.69 Million EUR | -24.01% |
| 2018 Q1 | -3.22 Million EUR | -22.81% |
| 2018 Q2 | -2.55 Million EUR | 20.68% |
| 2018 Q4 | -3.94 Million EUR | -32.65% |
| 2017 FY | -10.23 Million EUR | 8.3% |
| 2017 Q1 | -2.37 Million EUR | -96.68% |
| 2017 Q3 | -1.13 Million EUR | 72.24% |
| 2017 Q2 | -4.1 Million EUR | -73.12% |
| 2017 Q4 | -2.62 Million EUR | -130.2% |
| 2016 Q2 | -3.29 Million EUR | 23.82% |
| 2016 FY | -11.16 Million EUR | -24.22% |
| 2016 Q4 | -1.2 Million EUR | 48.46% |
| 2016 Q3 | -2.33 Million EUR | 29.04% |
| 2016 Q1 | -4.32 Million EUR | -354.31% |
| 2015 Q3 | -2.41 Million EUR | 1.95% |
| 2015 Q4 | -952 Thousand EUR | 60.51% |
| 2015 Q2 | -2.45 Million EUR | 22.28% |
| 2015 Q1 | -3.16 Million EUR | -7.33% |
| 2015 FY | -8.98 Million EUR | -1.48% |
| 2014 Q1 | -2.24 Million EUR | -2.8% |
| 2014 FY | -8.85 Million EUR | -19.47% |
| 2014 Q4 | -2.94 Million EUR | -60.04% |
| 2014 Q3 | -1.84 Million EUR | -1.04% |
| 2014 Q2 | -1.82 Million EUR | 18.62% |
| 2013 Q2 | -1.63 Million EUR | 4.49% |
| 2013 Q3 | -1.87 Million EUR | -14.52% |
| 2013 Q4 | -2.17 Million EUR | -16.09% |
| 2013 FY | -7.41 Million EUR | 39.24% |
| 2013 Q1 | -1.71 Million EUR | 38.27% |
| 2012 Q2 | -3.38 Million EUR | -44.82% |
| 2012 FY | -12.19 Million EUR | 21.69% |
| 2012 Q1 | -2.33 Million EUR | 51.87% |
| 2012 Q3 | -3.69 Million EUR | -9.07% |
| 2012 Q4 | -2.78 Million EUR | 24.72% |
| 2011 FY | -15.57 Million EUR | -35.72% |
| 2011 Q1 | -2.89 Million EUR | 7.31% |
| 2011 Q2 | -3.01 Million EUR | -4.19% |
| 2011 Q3 | -4.81 Million EUR | -59.95% |
| 2011 Q4 | -4.85 Million EUR | -0.87% |
| 2010 Q1 | -2.58 Million EUR | 17.89% |
| 2010 Q4 | -3.11 Million EUR | -4.84% |
| 2010 Q3 | -2.97 Million EUR | -6.4% |
| 2010 Q2 | -2.79 Million EUR | -7.96% |
| 2010 FY | -11.47 Million EUR | -12.26% |
| 2009 Q3 | -2.25 Million EUR | 5.68% |
| 2009 FY | -10.22 Million EUR | 16.69% |
| 2009 Q1 | -2.42 Million EUR | 0.0% |
| 2009 Q2 | -2.39 Million EUR | 1.16% |
| 2009 Q4 | -3.15 Million EUR | -39.7% |
| 2008 FY | -12.27 Million EUR | 6.69% |
| 2007 FY | -13.15 Million EUR | 14.61% |
| 2006 FY | -15.4 Million EUR | -275.26% |
| 2005 FY | 8.78 Million EUR | -19.93% |
| 2004 FY | 10.97 Million EUR | 63.56% |
| 2003 FY | 6.71 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | -216.562% |
| Arrayit Corporation | -3.31 Million USD | -34.622% |
| Atlantic International Corp. | -5.62 Million USD | 20.685% |
| Biocept, Inc. | -32.08 Million USD | 86.089% |
| Bioqual, Inc. | 483.48 Thousand USD | 1023.205% |
| CardioGenics Holdings Inc | -1.91 Million USD | -132.921% |
| DermTech, Inc. | -100.88 Million USD | 95.576% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 100.22% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 79.33% |
| iMD Companies, Inc. | -200.63 Thousand USD | -2124.687% |
| IDenta Corp. | 14.64 Thousand USD | 30580.217% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 656.549% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 11636.93% |
| InVitro International | 1553.00 USD | 287512.943% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 48.05% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -7580.897% |
| Medical Imaging Corp. | -3.02 Million USD | -47.651% |
| NovelStem International Corp. | -4.18 Million USD | -6.597% |
| Optigenex Inc. | -2.89 Million USD | -54.034% |
| PharmChem, Inc. | 845.1 Thousand USD | 628.164% |
| Proteome Sciences plc | -2.44 Million USD | -82.707% |
| Response Genetics, Inc | -20.18 Million USD | 77.886% |
| Rennova Health, Inc. | -3.29 Million USD | -35.544% |
| RushNet, Inc. | -607.02 Thousand USD | -635.308% |
| ScreenPro Security Inc. | -2.24 Million USD | -98.488% |
| Stella Diagnostics Inc. | -5.7 Million USD | 21.794% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 60.899% |
| Todos Medical Ltd. | -24.99 Million USD | 82.142% |